Hypertension treatment may be on the verge of its biggest breakthrough in decades, with scientists developing long-acting injectable therapies that could replace daily pills with just two shots a year.

What once sounded like science fiction is now moving closer to reality. Several such therapies are in late-stage clinical trials, and experts say they could dramatically improve blood pressure control worldwide.

A recent review in The Lancet highlights the urgency for new approaches. Despite effective medicines being available for years, global control of high blood pressure remains poor – largely because patients struggle to take daily medication consistently.

The Scale Of The “Silent Killer”

High blood pressure remains the leading risk factor for heart attacks, strokes and premature deaths globally. The World Health Organization defines hypertension as blood pressure at or above 140/90 mm Hg, while normal levels are below 120/80 mm Hg.

The global burden is enormous. Around 1.4 billion adults aged 30 to 79 — roughly one in three — live with hypertension, and nearly half are unaware of their condition. Even among those diagnosed, fewer than 25 percent achieve adequate control.

India reflects the same crisis. Studies estimate that about 315 million Indians have hypertension, yet large numbers remain untreated or poorly controlled. Missed doses, side effects, complex regimens and treatment fatigue all contribute to the problem.

Why Daily Pills Often Fail

Current treatment typically involves combinations of drugs such as ACE inhibitors, angiotensin receptor blockers, calcium channel blockers and diuretics. While effective in theory, these require strict daily adherence.

Many patients also take medicines for diabetes, obesity or cholesterol, leading to “polypharmacy” – multiple pills several times a day. Over time, this reduces compliance and effectiveness.

Long-acting injectables aim to solve this core problem. Instead of working downstream to lower blood pressure temporarily, new therapies target the underlying biological mechanisms driving hypertension.

Some candidates use small interfering RNA (siRNA) technology to suppress angiotensinogen production in the liver, thereby dampening the renin–angiotensin system – a key regulator of blood pressure. Others target inflammation or hormones such as aldosterone that influence fluid balance and vascular function.

Promise And Caution

The biggest advantage is durability. A twice-yearly injection could maintain stable drug levels, eliminate daily pill burden and significantly improve adherence. In theory, this could lead to fewer heart attacks and strokes over time.

However, experts urge caution. Cost could be a major barrier, especially in low- and middle-income countries where hypertension rates are highest. Previous injectable therapies for cholesterol reduction remain expensive and inaccessible to many.

Long-term safety is another key concern. Since hypertension is a lifelong condition, patients may need these treatments for decades. Extensive data on rare side effects and long-term outcomes will be essential before widespread use.

Even so, the potential impact is enormous. If proven safe, effective and affordable, twice-yearly injections could transform hypertension from a daily compliance struggle into a manageable long-term intervention offering new hope against one of the world’s deadliest silent diseases.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share